Association of IL-1β and IL-10 Polymorphisms with Prostate Cancer Risk and Grade of Disease in Eastern Croatian Population by Vesna Horvat et al.
393
V. Horvat et al.: IL-1β and IL-10 Polymorphisms and Prostate Cancer, Coll. Antropol. 38 (2014) 4: 393–400
Like other solid tumors, PCa is dependent on angiogen-
esis10 e.g. the ability to create new blood vessels which 
support its growth and allow penetration into the sur-
rounding tissues and metastatic spread11. Among others, 
the angiogenic factors include cytokines, which are known 
to have a key role in the regulation of humoral and cellular 
immune responses and play a role in the malignant proc-
ess12. They have a direct effect on the growth inhibition of 
tumor cells, lead to tumor regression, enhance antitumor 
immune effects, act as growth factors for tumor cells and 
can mediate paraneoplastic effects13.
Interleukin-1 (IL-1) is a pro-infl ammatory and pro-
angiogenic cytokine, primarily secreted by monocytes and 
Introduction
It is well known that the risk of cancer and subsequent 
neoplastic events (tumor growth, invasion, metastatic 
spread, response to therapy and survival) are strongly af-
fected by factors predetermined by the individual’s ge-
netic background1. There are also, an increasing amount 
of evidence that supports the importance of the genetic role 
in the etiology of prostate cancer (PCa)2–4. Studies on 
twins suggest that up to 50% risk of PC can be explained 
by genetic factors1,5.
PCa is the most common non-skin cancer among men 
in the USA and the EU6–8. In Croatia, PCa is in second 
place (following lung cancer) and in third place according 
to mortality9.
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A B S T R A C T
Single nucleotide polymorphisms (SNPs) in the promotor regions of cytokine genes included in angiogenesis may infl u-
ence prostate cancer (PCa) development via regulation of the pathways of tumor angiogenesis. The aim of the present 
study was to investigate the association of IL-1b+3954 (rs1143634) and IL-10-1082 (rs1800896) polymorphisms with PCa 
risk and aggressiveness in eastern Croatian patients. One hundred twenty PCa patients and 120 benign prostatic hyper-
plasia (BPH) controls were genotyped using real-time PCR (LightCycler Instrument, Roche Diagnostics) and the melting 
curve analysis method. There was no signifi cant difference in the frequency of genotypes for the two polymorphisms between 
PCa patients and controls (χ2=0.857, p=0.355 for IL-b1; χ2=0.026, p=0.872 for IL-10). Carriers of the IL-10-1082A>G vari-
ant were found to be associated with the Gleason score (GS)>7 (AA versus GA+GG, OR=3.47, 95% CI 1.11–10.88, p=0.033). 
There was no signifi cant difference in the frequency of genotypes for the two polymorphisms and the presence of meta-
static disease in PCa patients. These results suggest that tested SNPs associated with differential production of IL-1b 
and IL-10 are not risk factors for PCa and do not correlate with the presence of distant metastasis in eastern Croatians. 
We found that IL-10-1082 GA+/or GG carriers have a higher risk of developing PCa with GS>7 in eastern Croatians.
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macrophages. IL-1 family is composed of two glycoprotein 
IL-1a and IL-1b and IL-1 receptor antagonist (IL-1Ra)14. 
IL-1b acts on angiogenesis by direct action on vascular 
endothelial cells or by enhancing production of pro-ang-
iogenic factors via paracrine control. Together with IL-6 
it stimulates angiogenesis and the production of the vas-
cular endothelial growth factor (VEGF) in the cells of the 
cancer, and in glioma cells15. An antagonist of IL-1b recep-
tor inhibits angiogenesis and tumor growth, suggesting 
that the signalling through the IL-1b receptors is involved 
in infl ammation and tumor growth. Song et al. reported 
that IL-1b promotes tumor invasiveness, angiogenesis and 
suppresses the host immune system16. Experimental stud-
ies have shown the association of IL-1b with PCa17. Re-
gions of cytokine genes contain polymorphisms that di-
rectly influence cytokine production. These single 
nucleotide polymorphisms (SNPs) are associated with dif-
ferent levels of cytokine production and may cause inter-
individual differences and thus infl uence antitumor im-
mune responses18–20. SNPs in the IL-1b gene on chromosome 
2q14 are associated with increased production of IL-1b 
and increased risk of various types of cancer21–23. The most 
common examined polymorphisms are –511C>T in the 
promoter region and +3954C>T in exon 5 on IL-1b 
gene18,20,24–27.
Interleukin-10 (IL-10) is anti-infl ammatory and anti-
angiogenic cytokine secreted primarily by macrophages 
and T-lymphocytes. It seems that the effect of IL-10 on 
macrophages affect the regulation of angiogenesis in var-
ious cancers28–30, and its immunosuppressive and anti-
infl ammatory properties contribute to the growth of the 
tumor, enabling them to avoid immune responses. How-
ever, animal and in vitro studies have shown that a high 
value of IL-10 reduces tumor growth and angiogenesis31. 
SNPs in the IL-10 gene on chromosome 1 (1q31–1q32) low-
ers the production of IL-10 and increases cancer risk (can-
cer of the cervix, stomach, kidney, melanoma)32–34. The 
most commonly studied polymorphisms are the –1082A>G, 
–592C>A, –819C>T in the promoter region of IL-10 
gene19,27,35–37.
Although the results of the genetic variations of IL-1b 
and IL-10 and the association with cancer are contradic-
tory, animal studies and in vitro models support the hy-
pothesis of an association between a high production of 
IL-1b and a low production of IL-10 cytokines with tumori 
genesis in the prostate.
The aim of this case-control study was to evaluate the 
association between the IL-1b+3954C>T and IL-10-
1082A>G polymorphisms with the risk and aggressive-
ness of PCa in the eastern Croatian population.
Materials and Methods
Subjects
A total of 240 subjects from eastern Croatia were in-
cluded in the prospective, case-control study, 120 PCa 
patients and 120 benign prostatic hyperplasia (BPH) pa-
tients. They all were treated in the period of 2008–2010 at 
the Department of Urology, University Hospital Centre 
Osijek.
PCa and BPH patients had a digital rectal examina-
tion (DRE) and a serum prostate specifi c antigen (PSA) 
concentration determination. All patients with an elevat-
ed PSA concentration (>4ng/mL) and/or suspicious DRE 
were included in the study and they all underwent tran-
srectal ultrasound (TRUS) guided 12-core needle prostate 
biopsy. One hundred twenty patients had histological con-
fi rmation of PCa while another 120 patients had histo-
logical confi rmed BPH and therefore they represented 
controls. PCa patients were classifi ed according to their 
Gleason score (GS) in a less and moderately aggressive 
form with GS≤7 and a highly aggressive form with GS>7. 
According to the results of bone scintigraphy and com-
puted tomografy (CT) they also, were classifi ed as M0-no 
metastasis and M1-with metastasis. Groups were age 
matched. Subjects who had normal DRE and PSA<4 ng/
mL, or those with some other site of cancer were excluded 
from the study.
Before DRE and blood sampling each participant com-
pleted a pre-designed questionnaire with information re-
garding age, smoking status, alcohol consumption, associ-
ated medical history etc. (Table 1). A written informed 
consent was obtained from each participant.
The study was approved by the Ethics Committee of 
University Hospital Centre Osijek and Ministry of Sci-
ence, Education and Sports of the Republic of Croatia.
Blood sampling
Blood samples for each participant were collected by a 
puncture from an antecubital vein in serum separator 
tubes (BD Vacutainer, Becton Dickinson, Plymouth, UK) 
for PSA determination and K2EDTA tubes (BD Vacutain-
er, Becton Dickinson, Plymouth, UK) for analysing poly-
morphisms of interest.
Genotyping of the IL-1b (rs1143634) and IL-10 
(rs1800896)
Genomic DNA was extracted from 200 mL of periph-
eral blood samples by standard procedure using the High 
Pure PCR Template Preparation Kit (Roche, Mannheim, 
Germany). Real-time PCR and melting curve analysis 
were performed on LightCycler 1.5 Instrument (Roche, 
Mannheim, Germany). The PCR primers were synthe-
sized by Invitrogen (Paisley, UK) and fl uorescent-labelled 
probes by TIB MOLBIOL (Berlin, Germany).
Genotyping of the IL-1b+3954 SNP was performed as 
previously described in Palli et al35. Briefl y, a total reac-
tion volume of 10 mL contained of 1.5 mL of sample DNA, 
1x LC DNA Master Hybridization Probes Mix (Roche, 
Mannheim, Germany), 3.0 mM MgCl2, 0.5 mM primers 
each (5’-GTT GTC ATC AGA CTT TGA CC-3’ and 5’-TTC 
AGT TCA TAT GGA CCA GA-3’) and 0.15 mM hybridiza-
tion probes each (5’-CCT ATC TTC TTC GAC ACA TGG 
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TABLE 1









<50 3 (2.5) 3 (2.5)
50–59 18 (15.0) 13 (10.8)
60–69 48 (40.0) 54 (45.0)
70–79 46 (38.3) 50 (41.7)
≥80 5 (4.2) 0 (0)
 (X±SD) 67.5±7.8 67.6±6.6 0.961
Smoking status
Nonsmoking 70 (58.3) 88 (73.3)
Smoking 50 (41.2) 32 (26.7) 0.068
History of prostate cancer
No 110 (91.7) 113 (94.2)
Yes 10 (8.3) 7 (5.8) 0.463
PSA (ng/mL) 
≤10 46 (38.3) 29 (24.2)
>10 74 (61.7) 91 (75.8)
Median (IQR) 12.4 (6.7–35.1) 6.81 (5.1–9.5) <0.001
Body Mass Indeks (kg/m2)
<25 27 (22.9) 34 (29.1)
25–30 57 (48.3) 66 (56.4)







* p value of Mann-Whitney rank sum test, PCa – prostate carcino-
ma, BPH – benign prostatic hyperplasia, IQR-interquartile range
nheim, Germany), 4.0 mM MgCl2, 1.0 mM 5’-ATC CAA 
GAC AAC ACT ACT AAG GC-3’ primer, 0.5 mM 5’-GGG 
TGG GCT AAA TAT CCT CAA-3’ primer, 0.2 mM probes 
each (5’-GGA TAG GAG GTC CCT TAC TTT CCT CTT 
ACC-FL-3’ and 5’-LCRed640-CCC TAC TTC CCC CTC 
CCA AA-P-3’) and 0.5 mL DMSO (fi nal concentration 5%). 
The cycling program consisted of initial denaturation (30s 
at 94°C), amplifi cation (50 cycles: 5s at 94°C, 15s at 50°C, 
20s at 72°C) and melting curve acquisition (42°C to 78°C 
with temperature transition of 0.1 °C/s). In these condi-
tions melting temperatures of allele G and allele A were 
62.5°C and 53°C, respectively.
Statistical analysis
The Man-Whitney rank sum test was used to compare 
demographic and clinical characteristics between cases 
and controls. Allele frequencies were estimated and tested 
for fi t to the expectations of Hardy-Weinberg equilibrium 
(HWE). Genotype and allele frequencies between cases 
and controls and among GS and metastasis subgroups of 
PCa were compared by Chi-square (c2) statistics or Fisch-
er’s exact tests. Relative risk was estimated by the odds 
ratio (OR) and 95% confi dence interval (CI). The difference 
was considered statistically signifi cant when p<0.05. Sta-
tistical analyses were performed using MedCalc for Win-
dows, version 12.4.0.0 (MedCalc Software, Mariakerke, 
Belgium).
Results
Basic clinical and demographic characteristics of PCa 
patients and BPH controls with corresponding p values 
are shown in Table 1. The groups did not differ in age or 
hereditary PCa incidence. There was a difference in the 
number of smokers between the groups, although not sta-
tistically signifi cant. The number of obese people (BMI>30) 
was signifi cantly higher in the PCa group. There was a 
statistically signifi cant difference in PSA values between 
the PCa and BPH group (p=<0.001) with the interquartile 
range (IQR) signifi cantly higher in the PCa group. The 
BPH group has higher TRUS-assessed prostate volume 
values than the PCa patients. Among PCa patients, 23.7% 
had a GS>7 and 33.9% had distance metastases. Two pa-
tients did not have data about GS and M status and were 
not included in the statistical analysis. The distribution 
of genotypes for each SNP in the PCa and control group 
was in agreement with HWE.
Table 2 shows clinical and demographic characteristics 
of PCa patients with GS≤7 and GS>7 with corresponding 
p values. There was a statistically signifi cant difference 
in PSA values and the presence of distant metastasis be-
tween these groups (p=<0.001).
Comparison of genotypes and allele frequencies of IL-
1b+3954C>T and IL-10-1082A>G polymorphisms and cor-
responding OR for PCa risk are shown in Table 3. There 
was no signifi cant difference in the frequency of genotypes 
for the two polymorphisms between PCa patients and con-
G-FL-3’ and 5’-LCRed640-ACG AGG CTT ATG TGC ACG 
ATG C-P-3’). The PCR program consisted of initial dena-
turation (10 min at 95°C), amplifi cation (30 cycles: 10s at 
97°C, 10s at 63°C, 10s at 72°C, 35 cycles: 10s at 95°C, 10s 
at 58°C, 10s at 72°C) and melting curve acquisition (40°C 
to 80°C with temperature transition of 0.1 °C/s). Melting 
temperatures of allele C and allele T were 63°C and 55°C, 
respectively.
Genotyping of the IL-10-1082 polymorphism was per-
formed according to Timmann et al.36 with minor modifi -
cations. Briefl y, 2 mL of sample DNA were placed in a total 
volume of 10 mL of reaction solution also containing 1x LC 
DNA Master Hybridization Probes Mix (Roche, Man-
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TABLE 2









< 50 1 (1.1) 1 (3.6)
50–59 17 (18.9) 2 (7.1)
60–69 39 (43.3)  9 (32.1)
70–79 31 (34.4) 14 (50.0)
≥ 80 2 (2.2) 2 (7.1)
 (X±SD) 66.5 ± 7.4 70.3 ± 7.9 0.009
Smoking status
Nonsmoking  55 (61.1)  16 (59.3) 0.871
Smoking  35 (38.9)  11 (40.7)
History of prostate cancer
No 81 (90.0)  27 (96.4)
Yes  9 (10.0)  1 (3.6) 0.291
PSA (ng/mL) 
≤10 41 (45.6)  4 (14.3)
>10 49 (54.4)  24 (85.7)
Median (IQR) 10.4 (6.1–22.4) 33.9 (17.9–178.1) <0.001
Body Mass Indeks (kg/m2)
<25  17 (19.1)  10 (37.0)
25–30  44 (49.4)  12 (44.4)
>30  28 (31.5)  5 (18.5) 0.040
Distant metastasis
M0 69 (76.7)  9 (32.1)
M1 21 (23.3)  19 (67.9)  <0.001
* p value of Mann-Whitney test, not including missing values in all 
variables, GS-Gleason score, IQR-interquartile range
trols (c2=0.857, p=0.355 for IL-b1; c2=0.026, p=0.872 for 
IL-10).
In patients with PCa we made a linkage analysis of 
selected IL-1b and IL-10 SNPs with GS and the presence 
of distant metastases.
Table 4 shows a comparison of genotypes and allele 
frequencies of IL-1b+3954C>T and IL-10-1082A>G with 
GS in patients with PCa. There was no statistically sig-
nifi cant difference in the frequency of IL-1b genotypes and 
alleles between PCa patients by GS. IL-10-1082G allele 
polymorphism frequency was higher in PCa patients with 
GS>7, although not statistically signifi cant. IL-10-1082 
GA+/or GG genotype showed 3.47 times higher risk for 
PCa with GS>7.
Table 5 shows a comparison of genotype frequencies for 
IL-1b+3954C>T and IL-10-1082A>G due to the presence 
of distant metastases in patients with PCa. There was no 
statistical difference in the frequency of genotypes for IL-
1b and IL-10 polymorphisms and any correlation between 
the frequencies of these two polymorphisms and the pres-
ence of metastatic disease in PCa patients.
In addition, there were 14 wild type (IL-1b+3954CC/
IL-10-1082AA) double homozygotes in both groups, 24 
double heterozygotes (IL-1b+3954CT/IL-10-1082AG) in 
the BPH group and 32 in the PCa group, 1 mutant form 
double homozygote (IL-1b+3954TT/IL-10-1082GG) in the 
BPH group and 5 in the PCa group.
Discussion
The association of IL-1b+3954 and IL-10-1082 poly-
morphisms with PCa risk and aggressiveness were inves-
tigated in this prospective study, in eastern Croatian pa-
tients. Carriers of the IL-10-1082A>G variant were found 
to be associated with the GS>7 and IL-10-1082 GA+/or GG 
genotype showed 3.47 times higher risk for PCa with 
GS>7. No signifi cant difference was found in the frequen-
cy of genotypes for the two polymorphisms between PCa 
patients and controls. Also, there was no signifi cant dif-
ference in the frequency of genotypes for the two polymor-
phisms and the presence of metastatic disease in PCa 
patients.
PCa is like other types of cancer, an actively progres-
sive disease. It is imperative to establish mechanisms to 
identify people who are at risk of developing a more ag-
gressive form of PCa. Interindividual genetic variations 
can infl uence the interaction between cancer cells and 
hormones, growth factors, and the factors that infl uence 
tumor microenvironment, thus they may greatly contrib-
ute to the risk, aggressiveness, treatment outcome and 
prognosis of cancer.
Angiogenesis has an important part in many human 
malignancies including PCa. Cytokines, which have a key 
role in the regulation of humoral and cellular immune 
response and play a role in the malignant process, are also 
angiogenic factors. Polymorphisms in regions of cytokine 
genes directly infl uence cytokine production so they may 
infl uence PCa development via regulation of the antitumor 
immune response and/or pathways of tumor angiogenesis.
Angiogenic molecular epidemiological studies in PCa, 
suggested the possibility of predicting susceptibility and 
prognosis by analyzing genetic polymorphisms19.
In this study, we examined SNPs of two cytokines IL-
1b+3954 and IL-10-1082. They were selected because they 
have been reported to infl uence expression of their respec-
tive cytokine in vitro38. Therefore, we proposed that chang-
es in expression of these two cytokines may infl uence the 
process of angiogenesis.
Zabaleta et al. fi rst studied patients with gastric pre-
malignant lesions and showed an association of develop-
ment of multifocal atrophic gastritis with the presence of 
IL-1b+3954T allele39. They proposed allele IL-1b+3954T 
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no association with PCa risk40. Michaud et al.27 in the 
Prostate, Lung, Colorectal and Ovarian (PLCO) Screen-
ing trial with 1320 PCa cases (1213-White males, 
107-Black males) and 1842 controls (1443-White males, 
409-Black males) found no associations with the risk and 
aggressiveness of PCa with IL-1b+3954TT genotype. Our 
results show no association of IL-1b+3954TT genotype 
with aggressiveness of PCa or the presence of distant me-
tastasis. We found a slight increase in the risk of PCa with 
TABLE 3








CC 43 (35.8) 51 (42.5) 1.00
CT 60 (50.0) 59 (49.2) 1.21 (0.70–2.07) 0.498
TT 17 (14.2) 10 (8.3)0 2.02 (0.84–4.86) 0.118
CT+TT 77 (64.2) 69 (57.5) 1.32 (0.79–2.22) 0.290
C allele 146 (60.8)0 161 (67.1)0 1.00
T allele 94 (39.2) 79 (32.9) 1.31 (0.90–1.91) 0.154
IL-10-1082
 
AA 37 (30.8) 42 (35.0) 1.00
GA 59 (49.2) 54 (45.0) 1.24 (0.70–2.20) 0.464
GG 24 (20.0) 24 (20.0) 1.13 (0.55–2.33) 0.729
GA+GG 83 (69.2) 78 (65.0) 1.21 (0.70–2.07) 0.492
A allele 133 (55.4)0 138 (57.5)0 1.00
G allele 107 (44.6)0 102 (42.5)0 1.09 (0.76–1.56) 0.645
SNP – single nucleotide polymorphism, PCa – prostate carcinoma, BPH – benign prostatic hyperplasia, OR – odds ratio
TABLE 4








CC 33 (36.7)   9 (32.1) 1.00
CT 44 (48.9) 16 (57.1) 1.33 (0.52–3,39) 0.546
TT 13 (14.4)   3 (10.7) 0.85 (0.20–3.63) 0.822
CT+TT   57 (63.33) 19 (67.9) 1.22 (0.50–3.01) 0.663
C allele 110 (61.1)0 34 (60.7) 1.00
T allele 70 (38.9) 22 (39.3) 1.02 (0.55–1.88) 0.958
IL-10-1082
 
AA 33 (36.7)   4 (14.3) 1.00
GA 40 (44.4) 17 (60.7) 3.51 (1.07–11.44) 0.038
GG 17 (18.9)   7 (25.0) 3.40 (0.87–13.24) 0.078
GA+GG 57 (63.3) 24 (85.7) 3.47 (1.11–10.88) 0.033
A allele 106 (58.9)0 25 (44.6) 1.00
G allele 74 (41.1) 31 (55.4) 1.78 (0.97–0.25) 0.063
SNP – single nucleotide polymorphism, GS – Gleason score, OR – odds ratio
as a marker for those individuals who do not advance to 
more aggressive stage of the disease, since only a minor 
fraction of patients with multifocal atrophic gastritis 
progress to dysplasia and to gastric cancer. Afterward, 
they hypothesized if there is a correlation of IL-1b+3954 
polymorphism with PCa risk and aggressiveness. They 
found, on the contrary that Caucasian-American individ-
uals carrying IL-1b+3954TT genotype had a >3-fold risk 
of being diagnosed with aggressive PCa25 but there was 
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IL-1b+3954T allele, although it was not statistically sig-
nifi cant (p=0.118).
In our study there was no statistically signifi cant dif-
ference in the frequency of IL-10-1082 genotypes and al-
leles between PCa patients and controls. However, after 
comparing low/intermediate PCa grades with high-grade 
PC, we found that the risk of developing aggressive PCa 
tends to increase in patients with G allele, but without 
statistical signifi cance. IL-10-1082 GA and GG genotype 
carriers showed a 3.47-fold higher risk of developing PCa 
with GS>7. These results are partially in agreement with 
the study by Zabaleta et al.25. They found that IL-10-
1082GG genotype which correlate with high IL-10 produc-
tion, is not only associated with aggressive PCa disease 
but also with PCa risk. Nevertheless, we did not fi nd an 
association of IL-10-1082GG genotype with the presence 
of distant metastasis.
Conversely, McCarron et al.19 or Kesarwani et al.26 ob-
served a signifi cant positive association between IL-10-
1082AA genotype with low IL-10 production and increased 
odds ratio of developing PCa.
Neither Michaud et al.27 nor Eder et al.36 report any 
correlation between IL-10 expression and PCa risk status.
The cause of these differences remains unclear. It is 
not clear how IL-10 may play a dual role in the develop-
ment of malignancy. By suppressing the Th1 response and 
by inhibiting phagocytic functions, IL-10 may promote 
tumor cells to evade the immune system and promote un-
controlled metastasis. In contrast, higher levels of IL-10 
have been associated with reduced angiogenesis via reduc-
tion of VEGF expression29, controlling the progression of 
the tumor by limiting access to the blood supply.
TABLE 5








CC 26 (33.3) 16 (40.0) 1.00
CT 40 (51.3) 19 (47.5) 0.77 (0.34–1.77) 0.540
TT 12 (15.4)   5 (12.5) 0.68 (0.20–2.28) 0.529
CT+TT 52 (66.7) 24 (60.0) 0.75 (0.34–1.65) 0.475
C allele 92 (59.0) 51 (63.8) 1.00
T allele 64 (41.0) 29 (36.2) 0.82 (0.47–1.42) 0.477
IL-10-1082
 
AA 26 (33.3) 10 (25.0) 1.00
GA 37 (47.4) 21 (52.5) 1.47 (0.60–3.65) 0.399
GG 15 (19.2)   9 (22.5) 1.56 (0.52–4.70) 0.429
GA+GG 52 (66.7) 30 (75.0) 1.50 (0.64–3.53) 0.354
A allele 89 (57.1) 41 (51.2) 1.00
G allele 67 (42.9) 39 (48.8) 1.26 (0.73–2.17) 0.398
SNP – single nucleotide polymorphism, M – distant metastasis, OR – odds ratio
The lack of consistency of single SNP analysis in PCa 
susceptibility and aggressiveness may be due to several 
possibilities: the relatively minor effect that a single SNP 
may have in the expression or function of the gene, ge-
netic trait differences, the existence of distinct genetic 
polymorphisms among specifi c populations, ethnicities 
and geographic regions. Moreover as cancer is a multi-
factorial disease, individual exposures to various environ-
mental factors (smoking, environment exposures, infl am-
mation, viral infections and others) in combination with 
genetic susceptibility may have contributed to these varied 
results.
Due to the small number of double homozygotes and 
double heterozygotes in subgroups and low power of test-
ing, these comparisons have not been included in the 
study.
In summary, our results suggest that IL-1b+3954 pol-
ymorphism might not be risk factor of PCa development 
and aggressiveness. However, IL-10-1082- AG and GG 
genotypes may impact PCa aggressiveness in Croatians. 
Since angiogenic genes polymorphisms may affect disease 
outcomes, treatment responses and immunotherapy, fur-
ther target studies on the effects of SNPs are required to 
understand genetic susceptibility to PCa.
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POVEZANOST IL-1b I IL-10 POLIMORFIZAMA S RIZIKOM I PROGRESIJOM RAKA PROSTATE U 
POPULACIJI ISTOČNE HRVATSKE
S A Ž E T A K
Pojedinačni nuklearni polimorfi zmi (SNP) u promotorskim regijama gena citokina uključenih u angiogenezu, mogu 
utjecati na razvoj karcinoma prostate (PCa) regulacijom putova angiogeneze tumora. Cilj ove studije bio je istražiti 
povezanost IL-1b+3954 (rs1143634) i IL-10-1082 (rs1800896) polimorfi zama s rizikom i agresivnošću karcinoma prostate 
kod pacijenata iz istočne Hrvatske. 120 pacijenata s karcinomom prostate i 120 kontrola s benignom hiperplazijom 
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prostate (BPH) genotipizirani su metodom lančane reakcije polimerazom u stvarnom vremenu (eng. real-time PCR) i 
analizom krivulje temperature taljenja pomoću tehnologije LightCycler (Roche Diagnostics). Nije bilo značajne razlike 
u učestalosti genotipova za dva polimorfi zma između PCa bolesnika i kontrola (c2=0,857, p=0,355 za IL-b1; c2=0,026, 
p=0,872 za IL-10). Utvrđena je povezanost nosioca IL-10-1082A>G varijante s GS>7 (AA u odnosu na GA+GG, OR=3,47; 
95% CI 1.11 do 10,88, p=0,033). Nije bilo značajne razlike u učestalosti genotipova za dva polimorfi zma i prisutnosti 
metastatske bolesti u PCa bolesnika. Ovi rezultati sugeriraju da testirani SNP-ovi, povezani s različitom produkcijom 
IL-1b i IL-10, nisu čimbenici rizika za PCa i ne koreliraju s prisutnošću metastaza kod ispitanika u istočnoj Hrvatskoj. 
Otkrili smo da u istočnoj Hrvatskoj, nositelji IL-10-1082 GA +/ili GG genotipa imaju veći rizik razvoja PCa s GS>7.
